Pegvisomant
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-PEGVISOMANT |
|---|---|
| Type | Drug |
| Aliases | SomavertПегвісомант |
| Status | reviewed 2026-07-11 | pending_clinical_signoff |
| Diseases | DIS-PITUITARY-ADENOMA |
| Sources | SRC-NCCN-CNS-2025 |
Drug Facts
| Class | Growth hormone receptor antagonist (PEGylated GH analog) |
|---|---|
| Mechanism | PEGylated recombinant human growth-hormone-receptor antagonist. Binds GH receptors and blocks GH-induced receptor dimerization and downstream signal transduction, lowering IGF-1 production without lowering circulating GH levels — it does not directly shrink the somatotroph adenoma. Used for biochemically persistent/residual acromegaly (elevated IGF-1) after transsphenoidal surgery and/or somatostatin-analogue therapy, either as an add-on to continuing SSA or as monotherapy when SSA is not tolerated or effective. |
| Typical dosing | Loading dose 40 mg SC (under medical supervision), then 10 mg SC once daily; titrate in 5 mg increments every 4-6 weeks according to serum IGF-1, to a usual maintenance range of 10-30 mg/day (maximum 30 mg/day per product label). Confirm exact titration schedule with treating endocrinology team. |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-07-11 |
Notes
STUB pending clinical co-lead signoff (CHARTER §6.1 — dev-mode-exempted, safe to merge as draft content, not published/verified clinical advice). Pegvisomant is used for residual/persistent acromegaly per the Disease narrative, typically added to or substituted for somatostatin-analogue therapy after surgery. Does not lower GH/tumor size — IGF-1 is the biochemical target of titration.
Used By
Indications
IND-PITUITARY-ADENOMA-1L-ACROMEGALY-SURGERY-SSA- IND-PITUITARY-ADENOMA-1L-ACROMEGALY-SURGERY-SSA
Regimens
REG-PEGVISOMANT-ACROMEGALY- Pegvisomant for residual acromegaly (GH-receptor antagonist)